Rockefeller Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Rockefeller Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$335K	Sell	33,495 -1,387	-4%	-$12.5K	﹤0.01%	2294
2026 Q1	$332K	Buy	34,882 +8,085	+30%	+$62.8K	﹤0.01%	2204
2025 Q4	$209K	Buy	26,797 +21,472	+403%	+$155K	﹤0.01%	2344
2025 Q3	$40.4K	Sell	5,325 -20,217	-79%	-$168K	﹤0.01%	3015
2025 Q2	$229K	Buy	+25,542	New	+$238K	﹤0.01%	1698
2024 Q4	–	Sell	-26,400	Closed	-$201K	–	1658
2024 Q3	$201K	Buy	+26,400	New	+$201K	﹤0.01%	1606
2023 Q1	–	Sell	-3,800	Closed	-$43K	–	2155
2022 Q4	$43K	Hold	3,800	–	–	﹤0.01%	2450
2022 Q3	$47K	Hold	3,800	–	–	﹤0.01%	2379
2022 Q2	$40K	Sell	3,800 -28	-0.7%	-$289	﹤0.01%	2391
2022 Q1	$62K	Buy	3,828 +28	+0.7%	+$449	﹤0.01%	2198
2021 Q4	$52K	Hold	3,800	–	–	﹤0.01%	2198
2021 Q3	$54K	Hold	3,800	–	–	﹤0.01%	2098
2021 Q2	$60K	Hold	3,800	–	–	﹤0.01%	1992
2021 Q1	$38K	Buy	3,800 +500	+15%	+$5.16K	﹤0.01%	2002
2020 Q4	$24K	Hold	3,300	–	–	﹤0.01%	1926
2020 Q3	$11K	Hold	3,300	–	–	﹤0.01%	1978
2020 Q2	$16K	Hold	3,300	–	–	﹤0.01%	1736
2020 Q1	$7K	Buy	+3,300	New	+$9.09K	﹤0.01%	1844

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Rockefeller Capital Management's BCRX Position: Q2 2026 in Review

Rockefeller Capital Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 4% in Q2 2026, selling an estimated $12.5K and leaving 33,495 shares worth $335K. The position accounts for ﹤0.01% of the portfolio, ranked #2294.

Rockefeller Capital Management first reported a position in BCRX in Q1 2020 and has held it in 18 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Rockefeller Capital Management held 33,495 shares of BioCryst Pharmaceuticals worth $335K as of Q2 2026.
Rockefeller Capital Management sold 1,387 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $12.5K.
BioCryst Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #2294 holding.
Rockefeller Capital Management first reported a position in BioCryst Pharmaceuticals in Q1 2020 and has held it in 18 quarters since.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.